- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 23, 2019
Distillery Therapeutics
KRAS inhibitor combinations for improved therapeutic efficacy
BioCentury | Sep 15, 2016
Distillery Therapeutics
Therapeutics: Angiogenin ribonuclease RNase A family 5 (ANG)
BioCentury | Aug 15, 2016
Emerging Company Profile
Restraining translation
Bantam's eIF4E inhibitors disrupt oncogene translation and cancer metabolism
BioCentury | Jun 18, 2015
Distillery Techniques
Techniques: Crystal structure of myeloid leukemia cell differentiation protein (MCL1)
BioCentury | Apr 30, 2015
Distillery Therapeutics
Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); B cell lymphoma 2 (BCL-2; BCL2); Bcl-XL
BioCentury | Mar 26, 2012
Emerging Company Profile
BioMetrx: RASS restoration
BioMetrx developing plant-derived Rasstore to reduce prostate cancer growth
BioCentury | Nov 21, 2011
Product Development
Combo conundrums
What new approaches are needed to speed trials of cancer drug combinations
Items per page:
1 - 10 of 28